Physician profile
Gary C Few
NPI 1689653875
$5,449.61
in general payments reported to CMS, 2019-2025
24 companies · $958 in 2025
The $958 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $162 · 2021: $513 · 2022: $1,409 · 2023: $1,518 · 2024: $464 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,155.31 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Abbvie INC. | $965.65 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $650.86 | 2022-2025 | Infuse, Xiidra, Miebo |
| Biotissue Holdings INC. | $535.42 | 2022-2025 | |
| New World Medical,INC. | $414.78 | 2022-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $331.99 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $239.12 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $177.47 | 2019-2022 | |
| Oyster Point Pharma, INC. | $158.79 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $133.53 | 2019-2023 | Myday Contact Lens |
| Glaukos Corporation | $120.00 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.33 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $78.67 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $66.30 | 2020-2021 | |
| Harrow Eye, LLC | $60.34 | 2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.27 | 2020-2022 | |
| Akorn Operating Company LLC | $46.25 | 2021 | |
| Thea Pharma INC. | $34.99 | 2024-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $34.53 | 2021 | |
| Mallinckrodt Hospital Products INC. | $29.23 | 2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $25.37 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $19.89 | 2023 | Clarus |
| Astellas Pharma US INC | $16.92 | 2025 | Izervay |
| Akorn, INC. | $16.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Few listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.